What are the recommended pharmacologic treatment options for stable angina, including first‑line and second‑line agents, dosing, and contraindications?

Pharmacologic Treatment of Stable Angina

Beta-blockers are the preferred first-line antianginal therapy for stable angina, with aspirin, statins, and ACE inhibitors added for event prevention, followed by calcium channel blockers or long-acting nitrates as second-line agents when beta-blockers are contraindicated or symptoms persist. 1

First-Line Therapy

For Symptom Relief

Beta-blockers are the cornerstone of initial antianginal treatment 1:

• Selective beta-1 antagonists preferred: bisoprolol, metoprolol succinate, or nebivolol 1
• Titrate to full therapeutic dose for 24-hour ischemia protection 1
• Critical warning: Never stop abruptly—taper over 4 weeks to avoid rebound ischemia 1
• Contraindications: Asthma (absolute), sick sinus syndrome, high-grade AV block 1
• Use with caution in COPD (not contraindicated), symptomatic peripheral vascular disease 1

Sublingual nitroglycerin for immediate symptom relief 1:

• Use as needed for acute episodes and prophylactically before activities that trigger angina 1
• If sublingual ineffective, consider buccal preparations 1

For Event Prevention (Mortality/Morbidity Reduction)

All patients with stable angina require 1:

• Aspirin 75-150 mg daily (or clopidogrel 75 mg if aspirin contraindicated) 1
• Statin therapy for LDL cholesterol lowering 1
• ACE inhibitor 1
• Beta-blocker (especially if prior MI—strongest mortality benefit) 1

Second-Line Therapy

When Beta-Blockers Are Contraindicated or Not Tolerated

Choose from 1:

1. Long-acting calcium channel blockers (Class IIa, Level A) 1:

   • Amlodipine (dihydropyridine): Safe in heart failure, effective for angina and hypertension 1
   • Verapamil or diltiazem (non-dihydropyridines): Avoid in systolic dysfunction, sick sinus syndrome, or AV block 1
   • Avoid short-acting dihydropyridines without beta-blocker coverage 1

2. Long-acting nitrates (Class IIa, Level A) 1:

   • Oral or transdermal preparations
   • Critical: Must use with nitrate-free interval (8-12 hours) to prevent tolerance 1
   • Nitrate patches require ≥10 mg dosing 1
   • Contraindications: Hypertrophic cardiomyopathy, concurrent phosphodiesterase inhibitors 1

3. Ivabradine (Class IIa, Level A) 1:

   • Only for patients in sinus rhythm
   • Do not combine with non-dihydropyridine CCBs or strong CYP3A4 inhibitors 1
   • Not recommended if LVEF >40% without clinical heart failure 1

4. Ranolazine (Class IIb, Level C) 1:

   • Reasonable option for low heart rate/blood pressure patients 1
   • Particularly useful in microvascular angina 1

5. Nicorandil (Class IIb, Level C) 1:

   • Potassium channel activator
   • May be considered but safety in heart failure uncertain 1

6. Trimetazidine (Class IIb) 1:

   • Metabolic agent, reasonable for low heart rate/blood pressure 1

Combination Therapy Algorithm

Step 1: Optimize Beta-Blocker Monotherapy

• Titrate to maximum tolerated dose before adding second agent 1

Step 2: If Symptoms Persist on Beta-Blocker

Add (Class I, Level A) 1:

• Dihydropyridine CCB (amlodipine) as preferred combination 1
• OR long-acting nitrate (with nitrate-free interval) 1
• OR ivabradine (if sinus rhythm) 1

Step 3: If Symptoms Persist on Two Drugs

Consider adding 1:

• Ranolazine, nicorandil, or trimetazidine as third agent 1
• However: Evidence for triple therapy is limited; refer for revascularization consideration rather than empirically adding third drug 1

Critical Contraindications and Combinations to Avoid

• Never combine: Ivabradine + non-dihydropyridine CCB 1
• Never combine: Nitrates + phosphodiesterase inhibitors 1
• Avoid: Beta-blocker + non-dihydropyridine CCB (risk of excessive bradycardia/AV block) 1
• Avoid: Non-dihydropyridine CCBs in heart failure with reduced ejection fraction 1
• Avoid: Beta-blockers in asthma (absolute), use caution in COPD 1

Special Populations

Patients with Heart Failure and Angina

• Beta-blocker is mandatory first-line (reduces HF hospitalization and mortality) 1
• If beta-blocker intolerant: ivabradine, nitrates, or amlodipine 1

Vasospastic Angina

• Calcium channel blockers are first-line (high doses: verapamil up to 480 mg/day, diltiazem up to 260 mg/day, nifedipine up to 120 mg/day) 1
• Add long-acting nitrates if CCB monotherapy insufficient 1
• Beta-blockers may worsen vasospasm—avoid as monotherapy 1

Microvascular Angina

• Ranolazine or trimetazidine particularly effective 1
• Beta-blockers with ACE inhibitor and statin 1

Common Pitfalls

1. Nitrate tolerance: Occurs with continuous exposure; always ensure 8-12 hour nitrate-free interval 1
2. Beta-blocker withdrawal: Abrupt cessation causes rebound ischemia; taper over 4 weeks 1
3. Inadequate dose titration: Optimize monotherapy before adding second agent 1
4. Inappropriate triple therapy: Limited evidence; refer for revascularization instead 1
5. Short-acting dihydropyridines without beta-blocker: May increase adverse cardiac events 1